Capricor Therapeutics, Inc. (CAPR)
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with SARS-CoV-2. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in development stage for the potential prevention of COVID-19. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.
$162.37M
Dr. Linda Marbán Ph.D.
48.00
San Diego, CA
Jun 04, 2002
-5.61
$-0.89
0.48
1.37
-102.93%
-5.79
-0.21
14.06
6.09
1.37
-73.01%
-220.26%
Similar stocks (13)
IDEAYA Biosciences, Inc.
IDYA
Keros Therapeutics, Inc.
KROS
Soleno Therapeutics, Inc.
SLNO
AnaptysBio, Inc.
ANAB
MeiraGTx Holdings plc
MGTX
Cidara Therapeutics, Inc.
CDTX
Unicycive Therapeutics, Inc.
UNCY
NextCure, Inc.
NXTC
Akari Therapeutics, Plc
AKTX
Pulmatrix, Inc.
PULM
Moleculin Biotech, Inc.
MBRX
Phio Pharmaceuticals Corp.
PHIO
Bio-Path Holdings, Inc.
BPTH
ETF Exposure (21)
iShares Micro-Cap ETF
IWC
0.02849%
Vanguard Russell 2000 Growth Index Fund
VTWG
0.01%
iShares Russell 2000 Growth ETF
IWO
0.00714%
iShares Russell 2000 ETF
IWM
0.00428%
ProShares Ultra Russell2000
UWM
0.0015941598465214091%
iShares Russell 2000 Value ETF
IWN
0.00139%
ProShares UltraPro Russell2000
URTY
7.855381376570842e-4%
ProShares Hedge Replication ETF
HDG
6.698100634653652e-4%
Vanguard Balanced Index Fund Institutional Shares
VBAIX
0%
Vanguard Balanced Index Fund Admiral Shares
VBIAX
0%
Vanguard Balanced Index Fund
VBINX
0%
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Institutional Total Stock Market Index Fund Institutional Shares
VITNX
0%
Vanguard Institutional Total Stock Market Index Fund
VITPX
0%
Vanguard Total Stock Market Index Fund
VITSX
0%
Vanguard Russell 3000 Index Fund
VTHR
0%
Vanguard Total Stock Market Index Fund
VTI
0%
Vanguard Total Stock Market Index Fund
VTSAX
0%
Vanguard Russell 2000 Index Fund
VTWO
0%
Vanguard Russell 2000 Value Index Fund
VTWV
0%
Vanguard Extended Market Index Fund
VXF
0%
Similar stocks (13)
IDEAYA Biosciences, Inc.
IDYA
Keros Therapeutics, Inc.
KROS
Soleno Therapeutics, Inc.
SLNO
AnaptysBio, Inc.
ANAB
MeiraGTx Holdings plc
MGTX
Cidara Therapeutics, Inc.
CDTX
Unicycive Therapeutics, Inc.
UNCY
NextCure, Inc.
NXTC
Akari Therapeutics, Plc
AKTX
Pulmatrix, Inc.
PULM
Moleculin Biotech, Inc.
MBRX
Phio Pharmaceuticals Corp.
PHIO
Bio-Path Holdings, Inc.
BPTH
ETF Exposure (21)
iShares Micro-Cap ETF
IWC
0.02849%
Vanguard Russell 2000 Growth Index Fund
VTWG
0.01%
iShares Russell 2000 Growth ETF
IWO
0.00714%
iShares Russell 2000 ETF
IWM
0.00428%
ProShares Ultra Russell2000
UWM
0.0015941598465214091%
iShares Russell 2000 Value ETF
IWN
0.00139%
ProShares UltraPro Russell2000
URTY
7.855381376570842e-4%
ProShares Hedge Replication ETF
HDG
6.698100634653652e-4%
Vanguard Balanced Index Fund Institutional Shares
VBAIX
0%
Vanguard Balanced Index Fund Admiral Shares
VBIAX
0%
Vanguard Balanced Index Fund
VBINX
0%
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Institutional Total Stock Market Index Fund Institutional Shares
VITNX
0%
Vanguard Institutional Total Stock Market Index Fund
VITPX
0%
Vanguard Total Stock Market Index Fund
VITSX
0%
Vanguard Russell 3000 Index Fund
VTHR
0%
Vanguard Total Stock Market Index Fund
VTI
0%
Vanguard Total Stock Market Index Fund
VTSAX
0%
Vanguard Russell 2000 Index Fund
VTWO
0%
Vanguard Russell 2000 Value Index Fund
VTWV
0%
Vanguard Extended Market Index Fund
VXF
0%